Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 145

1 1. Majhail NS, Tao L, Bredeson C, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013; 19(10):1498–1501.

2 2. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28(6):1011–1016.

3 3. Majhail NS, Bajorunaite R, Lazarus HM, et al. Long‐term survival and late relapse in 2‐year survivors of autologous haematopoietic cell transplantation for Hodgkin and non‐Hodgkin lymphoma. Br J Haematol. 2009; 147(1):129–139.

4 4. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long‐term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007; 110(10):3784–3792.

5 5. Wingard JR, Majhail NS, Brazauskas R, et al. Long‐term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230–2239.

6 6. Sun CL, Francisco L, Kawashima T, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010; 116(17):3129–3139.

7 7. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft‐versus‐host disease. Blood. 2004; 104(12):3501–3506.

8 8. Newell LF, Flowers ME, Gooley TA, et al. Characteristics of chronic GVHD after cord blood transplantation. Bone Marrow Transplant. 2013; 48(10):1285–1290.

9 9. Miyamura K, Yamashita T, Atsuta Y, et al. High probability of follow‐up termination among AYA survivors after allogeneic hematopoietic cell transplantation. Blood Adv. 2019; 3(3):397–405.

10 10. Khera N, Chow EJ, Leisenring WM, et al. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2011; 17(7):995–1003.

11 11. Center for International Blood and Marrow Transplant Research (CIBMTR). Post‐transplant guidelines. 2012. Available from: https://www.cibmtr.org/ReferenceCenter/Patient/Guidelines/pages/index.aspx (accessed 24 August 2020).

12 12. Children's Oncology Group: Long‐term follow‐up guidelines for survivors of childhood, adolescent, and young adult cancers. 2018. Available from: http://www.survivorshipguidelines.org/ ().

13 13. Chow EJ, Anderson L, Baker KS, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: A children's oncology group report. Biol Blood Marrow Transplant. 2016; 22(5):782–795.

14 14. International Guideline Harmonization Group for Late Effects of Childhood Cancer. Available from: https://www.ighg.org/international‐guideline‐harmonization‐group/ (accessed 24 August 2020).

15 15. Shenoy S, Gaziev J, Angelucci E, al. Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: Consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2018; 24(7):1313–1321.

16 16. Heimall J, Buckley RH, Puck J, et al. Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017; 23(8):1229–1240.

17 17. Dietz AC, Savage SA, Vlachos A, et al. Late effects screening guidelines after hematopoietic cell transplantation for inherited bone marrow failure syndromes: Consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biol Blood Marrow Transplant. 2017; 23(9):1422–1428.

18 18. Hartz B, Marsh R, Rao K, et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood. 2016; 127(25):3281–3290.

19 19. Rose C, Ernst O, Hecquet B, et al. Quantification by magnetic resonance imaging and liver consequences of post‐transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica. 2007; 92(6):850–853.

20 20. Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004; 34(6):505–509.

21 21. Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassemia after bone marrow transplantation. Lancet. 1993; 342:1388–1391.

22 22. Trottier BJ, Burns LJ, Defor TE, et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2‐MRI‐measured liver iron content. Blood. 2013; 122:1678–1684.

23 23. St Pierre TG, Clark PR, Chua‐anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005; 105(2):855–861.

24 24. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008; 14(7):790–794.

25 25. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood. 1997; 90(3):994–998.

26 26. Mariotti E, Angelucci E, Agostini A, et al. Evaluation of cardiac status in iron‐loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol. 1998; 103(4):916–921.

27 27. Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft‐versus‐host disease: A task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2017; 23(2):211–234.

28 28. Baird K, Cooke K, Schultz KR. Chronic graft‐versus‐host disease (GVHD) in children. Pediatr Clin North Am. 2010; 57(1):297–322.

29 29. Zecca M, Prete A, Rondelli R, et al. Chronic graft‐versus‐host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002; 100(4):1192–1200.

30 30. Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(3):449–455.

31 31. Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019; 134(3):304–316.

32 32. Norkin M, Shaw BE, Brazauskas R, et al. Characteristics oflate fatal infections after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(2):362–368.

33 33. Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors and outcomes of sclerosis in patients with chronic graft‐versus‐host disease. Blood. 2013; 121(25):5098–5103.

34 34. Inamoto Y, Pidala J, Chai X, et al. Assessment of joint and fascia manifestations in chronic graft‐versus‐host disease. Arthritis and Rheumatology. 2014; 66(4):1044–1052.

35 35. Inamoto Y, Lee SJ, Onstad LE, et al. Refined National Institutes of Health response algorithm for chronic graft‐versus‐host disease in joints and fascia. Blood Adv. 2020; 4(1):40–46.

36 36. Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft‐versus‐Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015; 21(7):1167–1187.

37 37. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):e44–100.

38 38. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127(23):2824–2832.

39 39. Five things physicians and patients should question. Choosing Wisely ‐ An initiative of the ABIM Foundation. Available from: https://www.choosingwisely.org/wp‐content/uploads/2018/01/ASTCT‐CTTC‐Choosing‐Wisely‐List_2019.pdf (accessed 24 August 2020).

40 40. Suh DW, Ruttum MS, Stuckenschneider BJ, et al. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology. 1999; 106(8):1564–1570.

41 41. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft‐versus‐host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015; 21(6):984–999.

42 42. Galbán CJ, Boes JL, Bule M, et al. Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(10):1592–1598.

43 43. Bergeron A, Chevret S, Chagnon K, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015; 191(11):1242–1249.

44 44. Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(5):619–625.

45 45. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer‐‐a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2010; 19(1):170–181.

46 46. Shalitin S, Phillip M, Stein J, et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 2006; 37(12):11091117.

47 47. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109(4):1765–1772.

48 48. Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014; 32(3):191–198.

49 49. The Childhood Cancer Survivor Study: CCSS Cardiovascular Risk Calculator: St. Jude Childrens' Research Hospital. Available from: https://ccss.stjude.org/cvcalc (accessed 24 August 2020).

50 50. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med. 1995; 333(10):621–627.

51 51. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005; 24(1):63–66.

52 52. Argent E, Kainer G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant. 2003; 7(1):38–42.

53 53. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40(3):638–643.

54 54. Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid‐induced osteonecrosis. Clin Orthop Relat Res. 2000( 370):295–310.

55 55. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001( 386):173–178.

56 56. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG‐CoA reductase inhibitors in renal transplant recipients. Kidney Int. 2003; 63(1):360–364.

57 57. Prasad GV, Chiu R, Nash MM, Zaltzman JS. Statin use and bone mineral density in renal transplant recipients. Am J Transplant. 2003; 3(10):1320–1321.

58 58. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy (Review). Curr Med Res Opin. 2003; 19(6):540–556.

59 59. Fehr T, Kahlert C, Fierz W, et al. Statin‐induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004; 175(1):83–90.

60 60. Mach F. Statins as immunomodulatory agents. Circulation. 2004; 109(21 Suppl 1):II15–II17.

61 61. Pritchett JW. Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clin Orthop Relat Res. 2007; 456:233–237.

62 62. Armenian SH, Sun CL, Kawashima T, et al. Long‐term health‐related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011; 118(5):1413–1420.

63 63. Sudour H, Mainard L, Baumann C, et al. Focal nodular hyperplasia of the liver following hematopoietic SCT. Bone Marrow Transplant. 2009; 43(2):127–132.

64 64. Pillon M, Carucci NS, Mainardi C, et al. Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transplant. 2015; 50(3):414–419.

65 65. Hingorani S, Guthrie KA, Schoch G, et al. Chronic kidney disease in long‐term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007; 39:223–229.

66 66. Hingorani S. Chronic kidney disease after liver, cardiac, lung, heart‐lung, and hematopoietic stem cell transplant. Pediatr Nephrol. 2008; 23(6):879–888.

67 67. Hingorani SR, Seidel K, Lindner A, et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant. 2008; 14(12):1365–1372.

68 68. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCT‐associated thrombotic microangiopathy as multi‐system endothelial injury. Blood Reviews. 2015; 29(3):191–204.

69 69. Hingorani S. Kidney and bladder complications of hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. 5th edn. Chichester, UK: John Wiley & Sons, Ltd; 2016 pp. 1131–1141.

70 70. Vincent F, Costa MA, Rondeau E. Chronic renal failure: a nonmalignant late effect of allogeneic stem cell transplantation (Letter to the Editor). Blood. 2003; 102(7):2695–2696.

71 71. Barnett AH, Bain SC, Bouter P, et al. Angiotensin‐receptor blockade versus converting‐enzyme inhibition in type 2 diabetes and nephropathy. N Eng J Med. 2004; 351(19):1952–1961.

72 72. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review (Review). BMJ. 2004; 329(7470):828.

73 73. Petryk A, Bergemann TL, Polga KM, et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006; 91(3):899–905.

74 74. Kaste SC, Shidler TJ, Tong X, et al. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 33(4):435–441.

75 75. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002; 87(7):3136–3141.

76 76. Bar M, Ott SM, Lewiecki EM, et al. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020; 9:S1083–8791. doi: 10.1016/j.bbmt.2020.07.001. Online ahead of print. PMID: 32653624

77 77. Carpenter PA, Hoffmeister P, Chesnut CH III, et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2007; 13:683–690.

78 78. Kuhlen M, Bader P, Sauer M, et al. Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high‐risk or relapsed ALL ‐ results of the ALL‐SCT 2003 trial. Br J Haematol. 2018; 183(1):104–109.

79 79. Li X, Brazauskas R, Wang Z, et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014; 20(4):587–592.

80 80. Nishimura T, Matsumoto T, Nishino M, Tomita K. Histopathologic study of veins in steroid treated rabbits. Clin Orthop Relat Res. 1997( 334):37–42.

81 81. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br. 1995; 77(1):34–41.

82 82. Mont MA, Cherian JJ, Sierra RJ, et al. Nontraumatic osteonecrosis of the femoral head: Where do we stand today? A ten‐year update. J Bone Joint Surg Am. 2015; 97(19):1604–1627.

83 83. Chughtai M, Piuzzi NS, Khlopas A, et al. An evidence‐based guide to the treatment of osteonecrosis of the femoral head. Bone Joint J. 2017; 99–b(10):1267–1279.

84 84. Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019; 4(3):85–97.

85 85. Osmani F, Thakkar S, Vigdorchik J. The utility of conservative treatment modalities in the management of osteonecrosis. Bull Hosp Jt Dis. 2017; 75(3):186–192.

86 86. Li D, Yang Z, Wei Z, Kang P. Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA‐compliant meta‐analysis of animal studies and clinical trials. Sci Rep. 2018; 8(1):1450.

87 87. Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid‐related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009; 40(2):235–239.

88 88. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005( 435):164–170.

89 89. Hua KC, Yang XG, Feng JT, et al. The efficacy and safety of core decompression for the treatment of femoral head necrosis: a systematic review and meta‐analysis. J Orthop Surg Res. 2019; 14(1):306.

90 90. Sugioka Y, Hotokebuchi T, Tsutsui H. Transtrochanteric anterior rotational osteotomy for idiopathic and steroid‐induced necrosis of the femoral head. Indications and long‐term results. Clin Orthop Relat Res. 1992( 277):111–120.

91 91. Seki T, Hasegawa Y, Masui T, et al. Quality of life following femoral osteotomy and total hip arthroplasty for nontraumatic osteonecrosis of the femoral head. J Orthop Sci. 2008; 13(2):116–121.

92 92. Powell GF, Brasel JA, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. I. Clinical evaluation of the syndrome. N Eng J Med. 1967; 276(23):1271–1278.

93 93. Powell GF, Brasel JA, Raiti S, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinologic evaluation of the syndrome. N Eng J Med. 1967; 276(23):1279–1283.

94 94. Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid‐induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab. 1998; 83(8):2824–2829.

95 95. Tejani A, Butt KM, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation. 1989; 47(2):229–233.

96 96. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate‐day corticosteroid treatment after kidney transplantation. J Pediatr. 1992; 120(5):721–725.

97 97. Reimer LG, Morris HG, Ellis EF. Growth of asthmatic children during treatment with alternate‐day steriods. J Allergy Clin Immunol. 1975; 55(4):224–231.

98 98. Ketterl TG, Chow EJ, Leisenring WM, et al. Adipokines, inflammation, and adiposity in hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2018; 24(3):622–626.

99 99. Armenian SH, Chemaitilly W, Chen M, et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: The cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transplant. 2017; 23(2):201–210.

100 100. Kamel A, Norgren S, Elimam A, et al. Effects of growth hormone treatment in obese prepubertal boys. J Clin Endocrinol Metab. 2000; 85(4):1412–1419.

101 101. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years experience. Blood. 2009; 113(2):306–308.

102 102. Vexiau P, Perez‐Castiglioni P, Socié G, et al. The 'euthyroid sick syndrome': incidence, risk factors and prognostic value soon after allogeneic bone marrow transplantation. Br J Haematol. 1993; 85(4):778–782.

103 103. Lee V, Cheng PS, Chik KW, et al. Autoimmune hypothyroidism after unrelated haematopoietic stem cell transplantation in children. J Pediatr Hematol/Oncol. 2006; 28(5):293–295.

104 104. Karthaus M, Gabrysiak T, Brabant G, et al. Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplant. 1997; 20(8):697–699.

105 105. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft‐vs‐host disease and immune recovery. Exp Hematol. 2006; 34(3):389–396.

106 106. Lortan JE, Rochfort NC, el Tumi M, Vellodi A. Autoantibodies after bone marrow transplantation in children with genetic disorders: relation to chronic graft‐versus‐host disease. Bone Marrow Transplant. 1992; 9(5):325–330.

107 107. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003; 361(9372):1881–1893.

108 108. Krasner AS. Glucocorticoid‐induced adrenal insufficiency. J Am Med Assoc. 1999; 282(7):671–676.

109 109. Oelkers W. Adrenal insufficiency (Review). N Eng J Med. 1996; 335(16):1206–1212.

110 110. Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in long‐term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol/Oncol. 2004; 26(2):81–90.

111 111. Jim HS, Sutton SK, Jacobsen PB, et al. Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation. Cancer. 2016; 122(8):1290–1297.

112 112. Baker KS, Leisenring WM, Goodman PJ, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood. 2019; 133(26):2790–2799.

113 113. Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li‐Fraumeni syndrome. Clin Cancer Res. 2017; 23(11):e38–e45.

114 114. Naldi L, Adamoli L, Fraschini D, et al. Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia. Cancer. 1996; 77(7):1402–1408.

115 115. Taitz J, Cohn RJ, White L, et al. Osteochondroma after total body irradiation: an age‐related complication. Pediatr Blood Cancer. 2004; 42(3):225–229.

116 116. Armenian SH, Sun CL, Francisco L, et al. Health behaviors and cancer screening practices in long‐term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant. 2012; 47(2):283–290.

117 117. van de Poll‐Franse LV, Nicolaije KA, Ezendam NP. The impact of cancer survivorship care plans on patient and health care provider outcomes: a current perspective. Acta Oncol. 2017; 56(2):134–138.

118 118. Majhail NS, Murphy E, Laud P, et al. Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. Haematologica. 2019; 104(5):1084–1092.

119 119. Hashmi SK, Lee SJ, Savani BN, et al. ASBMT practice guidelines committee survey on long‐termfollow‐up clinics for hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2018; 24(6):1119–1124.

120 120. Hashmi S, Carpenter P, Khera N, et al. Lost in transition: the essential need for long‐term follow‐up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant. 2014; 21(2):225–232.

121 121. Carpenter PA. How I conduct a comprehensive chronic graft‐versus‐host disease assessment [Commentary]. Blood. 2011; 118(10):2679–2687.

122 122. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost‐effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med. 2020; 172(1):22–29.

123 123. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68(32):698–702.

124 124. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow‐up. Haematologica. 2018; 103(1):30–39.